A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.

Abstract

Phase I-II clinical trials refer to the class of designs that evaluate both the safety and efficacy of a novel therapeutic agent in a single trial. Typically, Phase I-II oncology trials take the form of dose-escalation studies, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher doses until… (More)
DOI: 10.1002/sim.7087

Topics

3 Figures and Tables

Cite this paper

@article{Cunanan2017ABA, title={A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.}, author={Kristen M. Cunanan and Joseph S Koopmeiners}, journal={Statistics in medicine}, year={2017}, volume={36 1}, pages={43-53} }